<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04083599</url>
  </required_header>
  <id_info>
    <org_study_id>GCT1042-01</org_study_id>
    <nct_id>NCT04083599</nct_id>
  </id_info>
  <brief_title>GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors</brief_title>
  <official_title>A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genmab</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioNTech SE</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genmab</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and anti-tumor activity of GEN1042 in patients with metastatic or&#xD;
      locally advanced solid tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multicenter phase 1/2 study designed to assess the safety,&#xD;
      pharmacokinetics, pharmacodynamics and activity of GEN1042 administered as a monotherapy or&#xD;
      in combination in subjects with metastatic or locally advanced solid tumors. The trial&#xD;
      consists of 4 parts: a GEN1042 monotherapy dose escalation (phase 1a), a GEN1042 monotherapy&#xD;
      expansion (phase 2a), a combination therapy safety run in (phase 1b), and a combination&#xD;
      therapy expansion (phase 2b).&#xD;
&#xD;
      The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D)&#xD;
      has been determined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2019</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Dose-Limiting Toxicities (DLT) assessed by the Investigator to be possibly, probably or definitely related to GEN1042 (phase 1a) and GEN1042 combination regimen (phase 1b)</measure>
    <time_frame>First Cycle (21 days), assessed up to 36 months after the last subject's first treatment in the trial.</time_frame>
    <description>Percentage of Subjects With Dose-Limiting Toxicities (DLT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) assessed as the highest dose of GEN1042 administered alone (phase 1a) or in combination regimen (phase 1b)</measure>
    <time_frame>First Cycle (21 days), assessed up to 36 months after the last subject's first treatment in the trial.</time_frame>
    <description>Maximum Tolerated Dose (MTD) of GEN1042</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) based on available safety and dosing information of GEN1042 administered alone (phase 1a) and in combination regimen (phase 1b)</measure>
    <time_frame>First Cycle (21 days), assessed up to 36 months after the last subject's first treatment in the trial.</time_frame>
    <description>Recommended Phase 2 Dose of GEN1042</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Best Overall Response Rate (ORR) assessed by investigator using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 for dose expansion as monotherapy (phase 2a) and in combination (phase 2b)</measure>
    <time_frame>Baseline up to PD or start of the next line of treatment or death due to any cause, whichever occurs first, assessed up to 36 months after the last subject's first treatment in the trial.</time_frame>
    <description>Percentage of subjects with best Overall Response Rate (ORR), as determined by Investigator using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation: Area Under the Concentration Time Curve (AUC) of GEN1042</measure>
    <time_frame>Cycle (Cy) 1 Day (D) 1 before GEN1042 infusion (BI) and , End of GEN1042 Infusion (EOI), Cy1 D2, 3, 8, 15, Cy2 BI, EOI on D1, D 2, 3, 8, 15, and then D1 of Cy 3, 5, 7, 11, 15 and every 4 cycles thereafter (up to end of treatment) (Cy =21 days)</time_frame>
    <description>Pharmacokinetic (PK) parameters of GEN1042, and incidence of anti-drug antibodies Dose Escalation: Area Under the Concentration Time Curve (AUC) of GEN1042</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation: Maximum Concentration (Cmax) of GEN1042</measure>
    <time_frame>Cycle (Cy) 1 Day (D) 1 before GEN1042 infusion (BI) and End of Infusion (EOI), Cy1 D2, 3, 8, 15, Cy2 BI, EOI on D1, D 2, 3, 8, 15, and then D1 of Cy 3, 5, 7, 11, 15 and every 4 cycles thereafter (up to end of treatment) (Cy =21 days)</time_frame>
    <description>Pharmacokinetic (PK) parameters of GEN1042, and incidence of anti-drug antibodies Dose Escalation: Maximum Concentration (Cmax) of GEN1042</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation: Half-life (t1/2) of GEN1042</measure>
    <time_frame>Cycle (Cy) 1 Day (D) 1 before GEN1042 infusion (BI) and End of Infusion (EOI), Cy1 D2, 3, 8, 15, Cy2 BI, EOI on D1, D 2, 3, 8, 15, and then D1 of Cy 3, 5, 7, 11, 15 and every 4 cycles thereafter (up to end of treatment) (Cy =21 days)</time_frame>
    <description>Dose Escalation: Half-life (t1/2) of GEN1042</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Expansion: Area Under the Concentration Time Curve (AUC) of GEN1042</measure>
    <time_frame>Cy 1 BI, EOI on D1, D8, 15, Cy 2 BI, EOI on D1, D8, 15, and then D1 of Cy 3, 5, 7, 11, 15 and every 4 cycles thereafter (up to end of treatment) (Cy =21 days)</time_frame>
    <description>Dose Expansion: Area Under the Concentration Time Curve (AUC) of GEN1042</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Expansion: Maximum Concentration (Cmax) of GEN1042</measure>
    <time_frame>Cy 1 BI, EOI on D1, D8, 15, Cy 2 BI, EOI on D1, D8, 15, and then D1 of Cy 3, 5, 7, 11, 15 and every 4 cycles thereafter (up to end of treatment) (Cy =21 days)</time_frame>
    <description>Dose Expansion: Maximum Concentration (Cmax) of GEN1042</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation: Percentage of Participants with Incidence of anti-drug antibody (ADAs) responses to GEN1042</measure>
    <time_frame>BI on Cy 1, 2, 3, 5, 7, 11, 15 and every 4 cycles thereafter (up to end of treatment), safety follow-up visit (SFU) (30 and 90 days post final dose) (Cy =21 days)</time_frame>
    <description>Dose Escalation: Percentage of Participants with Incidence of anti-drug antibody (ADAs) responses to GEN1042</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Expansion: Percentage of Participants with Incidence of ADA response to GEN104</measure>
    <time_frame>BI on Cy 1, 2, 3, 5, 7, 11, 15 and every 4 cycles thereafter (up to end of treatment), SFU (30 and 90 days post final dose) (Cy =21 days)</time_frame>
    <description>Dose Expansion: Percentage of Participants with Incidence of ADA response to GEN104</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events and Serious Adverse Events as assessed by NCI CTCAE V5.0 for GEN1042 administered alone (phase 1a) and in combination regimen (phase 1b)</measure>
    <time_frame>Baseline up to 90 Days After the Last Dose, assessed up to 36 months after the last subject's first treatment in the trial.</time_frame>
    <description>Percentage of Subjects with Adverse Events and Serious Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) determined by Investigator using RECIST 1.1 for dose expansion as monotherapy (phase 2a) and in combination (phase 2b)</measure>
    <time_frame>Baseline up to PD or start of the next line of treatment or death due to any cause, whichever occurs first, assessed up to 36 months after the last subject's first treatment in the trial.</time_frame>
    <description>Progression-Free Survival (PFS), as Determined by Investigator Using RECIST Version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Object Response (DOR) determined by Investigator per RECIST 1.1. for dose expansion as monotherapy (phase 2a) and in combination (phase 2b)</measure>
    <time_frame>Baseline up to PD or start of the next line of treatment or death due to any cause, whichever occurs first, assessed up to 36 months after the last subject's first treatment in the trial.</time_frame>
    <description>Duration of Objective Response, as Determined by Investigator Using RECIST Version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival assessed from the start of study treatment to death for dose expansion as monotherapy (phase 2a) and in combination (phase 2b)</measure>
    <time_frame>From the start of study treatment until death due to any cause, assessed up to 36 months after the last subject's first treatment in the trial.</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events and Serious Adverse Events as assessed by NCI CTCAE V5.0 for dose expansion as monotherapy (phase 2a) and in combination (phase 2b)</measure>
    <time_frame>Baseline up to 90 Days After the Last Dose, assessed up to 36 months after the last subject's first treatment in the trial.</time_frame>
    <description>Percentage of Subjects with Adverse Events and Serious Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">447</enrollment>
  <condition>Malignant Solid Tumor</condition>
  <condition>Non Small Cell Lung Cancer (NSCLC)</condition>
  <condition>Colorectal Cancer (CRC)</condition>
  <condition>Melanoma</condition>
  <condition>Head and Neck Squamous Cell Carcinoma (HNSCC)</condition>
  <condition>Pancreatic Ductal Adenocarcinoma (PDAC)</condition>
  <arm_group>
    <arm_group_label>GEN1042 monotherapy dose escalation (phase 1a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• All NON-CNS solid tumors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEN1042 monotherapy expansion (phase 2a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NSCLC&#xD;
Melanoma&#xD;
CRC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination safety run-in (phase 1b) for NSCLC, HNSCC and Melanoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1L NSCLC&#xD;
1L HNSCC&#xD;
1L Melanoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination safety run-in (phase 1b) for HNSCC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• 1L HNSCC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination safety run-in (phase 1b) for PDAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• 1L PDAC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination therapy expansion (phase 2b) for Melanoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• 1L Melanoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination therapy expansion (phase 2b) for NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• 1L NSCLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination therapy expansion (phase 2b) for HNSCC with pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• 1L HNSCC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination therapy expansion (phase 2b) for HNSCC with pembrolizumab + chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• 1L HNSCC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination therapy expansion (phase 2b) for PDAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• 1L PDAC</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEN1042</intervention_name>
    <description>GEN1042 administered intravenously every 21 days (1Q3W).</description>
    <arm_group_label>Combination safety run-in (phase 1b) for HNSCC</arm_group_label>
    <arm_group_label>Combination safety run-in (phase 1b) for NSCLC, HNSCC and Melanoma</arm_group_label>
    <arm_group_label>Combination safety run-in (phase 1b) for PDAC</arm_group_label>
    <arm_group_label>Combination therapy expansion (phase 2b) for HNSCC with pembrolizumab</arm_group_label>
    <arm_group_label>Combination therapy expansion (phase 2b) for HNSCC with pembrolizumab + chemotherapy</arm_group_label>
    <arm_group_label>Combination therapy expansion (phase 2b) for Melanoma</arm_group_label>
    <arm_group_label>Combination therapy expansion (phase 2b) for NSCLC</arm_group_label>
    <arm_group_label>Combination therapy expansion (phase 2b) for PDAC</arm_group_label>
    <arm_group_label>GEN1042 monotherapy dose escalation (phase 1a)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab administered intravenously every 21 days (1Q3W).</description>
    <arm_group_label>Combination safety run-in (phase 1b) for HNSCC</arm_group_label>
    <arm_group_label>Combination safety run-in (phase 1b) for NSCLC, HNSCC and Melanoma</arm_group_label>
    <arm_group_label>Combination safety run-in (phase 1b) for PDAC</arm_group_label>
    <arm_group_label>Combination therapy expansion (phase 2b) for HNSCC with pembrolizumab</arm_group_label>
    <arm_group_label>Combination therapy expansion (phase 2b) for HNSCC with pembrolizumab + chemotherapy</arm_group_label>
    <arm_group_label>Combination therapy expansion (phase 2b) for Melanoma</arm_group_label>
    <arm_group_label>Combination therapy expansion (phase 2b) for NSCLC</arm_group_label>
    <arm_group_label>Combination therapy expansion (phase 2b) for PDAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cis-/carboplatin + 5FU administered intravenously in combination with GEN1042 + pembrolizumab 1Q3W for 6 cycles followed by GEN1042 +pembrolizumab 1Q3W.</description>
    <arm_group_label>Combination safety run-in (phase 1b) for HNSCC</arm_group_label>
    <arm_group_label>Combination therapy expansion (phase 2b) for HNSCC with pembrolizumab + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Cis-/carboplatin + 5FU administered intravenously in combination with GEN1042 + pembrolizumab 1Q3W for 6 cycles followed by GEN1042 +pembrolizumab 1Q3W.</description>
    <arm_group_label>Combination safety run-in (phase 1b) for HNSCC</arm_group_label>
    <arm_group_label>Combination therapy expansion (phase 2b) for HNSCC with pembrolizumab + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>Cis-/carboplatin + 5FU administered intravenously in combination with GEN1042 + pembrolizumab 1Q3W for 6 cycles followed by GEN1042 +pembrolizumab 1Q3W.</description>
    <arm_group_label>Combination safety run-in (phase 1b) for HNSCC</arm_group_label>
    <arm_group_label>Combination therapy expansion (phase 2b) for HNSCC with pembrolizumab + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>a: GEN1042 1Q3W+ gemcitabine + nab-paclitaxel 2Q3W for a total of 8 cycles; b: GEN1042 + pembrolizumab 1Q3W+ gemcitabine + nab-paclitaxel 2Q3W for 8 cycles followed by GEN1042 + pembrolizumab 1Q3W</description>
    <arm_group_label>Combination safety run-in (phase 1b) for PDAC</arm_group_label>
    <arm_group_label>Combination therapy expansion (phase 2b) for PDAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-Paclitaxel</intervention_name>
    <description>a: GEN1042 1Q3W+ gemcitabine + nab-paclitaxel 2Q3W for a total of 8 cycles; b: GEN1042 + pembrolizumab 1Q3W+ gemcitabine + nab-paclitaxel 2Q3W for 8 cycles followed by GEN1042 + pembrolizumab 1Q3W</description>
    <arm_group_label>Combination safety run-in (phase 1b) for PDAC</arm_group_label>
    <arm_group_label>Combination therapy expansion (phase 2b) for PDAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEN1042</intervention_name>
    <description>GEN1042 administered intravenously every 21 days (1Q3W) as per the recommended Phase 2 dose (RP2D) from monotherapy dose escalation.</description>
    <arm_group_label>GEN1042 monotherapy expansion (phase 2a)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Phase 1a:&#xD;
&#xD;
        • Subjects with non-CNS solid tumors that is metastatic or unresectable and for whom there&#xD;
        is no available standard therapy.&#xD;
&#xD;
        Phase 2a:&#xD;
&#xD;
        • Subjects with a confirmed diagnosis of relapsed or refractory, advanced and/or metastatic&#xD;
        melanoma, NSCLC, or CRC and for whom there is no available standard therapy&#xD;
&#xD;
        Phase 1b/Phase 2:&#xD;
&#xD;
          -  Subjects with unresectable Stage III or Stage IV melanoma with no prior systemic&#xD;
             anticancer therapy for unresectable or metastatic disease. Primary ocular or mucosal&#xD;
             melanoma is excluded.&#xD;
&#xD;
          -  Subjects with Stage IV metastatic or recurrent NSCLC with no prior systemic anticancer&#xD;
             therapy, no actionable mutation and tumor demonstrating PD-L1 expression in ≥1% of&#xD;
             tumor cells (TPS ≥1%).&#xD;
&#xD;
          -  Subjects with recurrent or metastatic HNSCC with no prior systemic therapy&#xD;
             administered in the recurrent or metastatic setting and tumor demonstrating PD-L1 IHC&#xD;
             CPS ≥1.&#xD;
&#xD;
          -  Subjects with confirmed metastatic PDAC with no previous radiotherapy, surgery,&#xD;
             chemotherapy, or investigational therapy for the treatment of metastatic disease.&#xD;
&#xD;
        General (all phases):&#xD;
&#xD;
        Dose Escalation and Expansion:&#xD;
&#xD;
          -  Must be age ≥ 18 years of age&#xD;
&#xD;
          -  Measurable disease according to RECIST 1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-1&#xD;
&#xD;
          -  Normal or adequate liver, renal, cardiac and bone marrow function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Phase 1a/Phase 2a&#xD;
&#xD;
          -  Treatment with an anti-cancer agent (within 21 days or after at least 5 half-lives of&#xD;
             the drug, whichever is shorter), prior to GEN1042 administration&#xD;
&#xD;
          -  Radiotherapy within 14 days prior to first GEN1042 administration&#xD;
&#xD;
          -  Toxicities from previous anti-cancer therapies that have not resolved&#xD;
&#xD;
        Phase 1b/Phase 2&#xD;
&#xD;
          -  Has received prior systemic cytotoxic chemotherapy, biological therapy, OR major&#xD;
             surgery within 3 weeks or at least 5 half-lives of the drug (whichever is shorter) of&#xD;
             the first dose of trial treatment.&#xD;
&#xD;
          -  Radiotherapy within 14 days of start of trial treatment or received lung radiation&#xD;
             therapy of &gt; 30 Gy within 6 months of the first dose of trial treatment.&#xD;
&#xD;
        General (all phases)&#xD;
&#xD;
          -  Subject has an active, known, or suspected autoimmune disease.&#xD;
&#xD;
          -  History of non-infectious pneumonitis that required steroids or currently has&#xD;
             pneumonitis.&#xD;
&#xD;
          -  History of ≥ grade 3 allergic reactions to monoclonal antibody (mAb) therapy&#xD;
&#xD;
          -  Subject with a condition requiring systemic treatment with either corticosteroids (&gt;10&#xD;
             mg daily prednisone equivalent) or other immunosuppressive medications within 14 days&#xD;
             of first treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Genmab A/S Trial Information</last_name>
    <phone>+4570202728</phone>
    <phone_ext>+4570202728</phone_ext>
    <email>clinicaltrials@genmab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patricia LoRusso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Haggstrom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Crystal Denlinger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>cann.researchreferrals@scresearch.net</last_name>
    </contact>
    <investigator>
      <last_name>Melissa Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet (Copenhagen University Hospital)</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kristoffer Rohrberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen am Rhein gGmbH</name>
      <address>
        <city>Ludwigshafen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>E Dippel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, University of Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>C Loquai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsmedizin Mannheim Dermatologie</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J Utikal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A Gesierich</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E Felip</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HM CIOCC Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M De Miguel Luken</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E Grande</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>START Madrid - Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>V Moreno</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>I Melero</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Juanita Lopez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 6, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

